Devalingam Mahalingam MD, PhD

Devalingam Mahalingam, MD, PhD, is a professor of medicine in the Division of Hematology-Oncology at the Northwestern University Feinberg School of Medicine. He also serves as the director of the clinical trials office, the director of developmental therapeutics (DT), and the director of the DT Fellowship Program at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. Dr. Mahalingam’s clinical research involves early drug development with a focus on gastrointestinal malignancies. Through participation in these early clinical studies, Dr. Mahalingam has run parallel experiments with novel compounds in the laboratory to evaluate the efficacy of combination therapies, evaluate resistance to therapies, identify mechanisms to overcome resistance and investigate the roles of apoptosis/autophagy in cancer development. Further, he has an interest in oncolytic viral therapy as a targeted approach to cancer cell eradication and its immuno-modulatory effects.